{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:03:21Z","timestamp":1783663401537,"version":"3.55.0"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40272-025-00710-9","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T09:43:19Z","timestamp":1759570999000},"page":"43-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent Advances in the Management of Seizures in Children"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-7933","authenticated-orcid":false,"given":"Frank M. C.","family":"Besag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-3531","authenticated-orcid":false,"given":"Michael J.","family":"Vasey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7256-3027","authenticated-orcid":false,"given":"Richard F. M.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"issue":"2","key":"710_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1684\/epd.2015.0736","volume":"17","author":"P Camfield","year":"2015","unstructured":"Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015;17(2):117\u201323. https:\/\/doi.org\/10.1684\/epd.2015.0736.","journal-title":"Epileptic Disord"},{"key":"710_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.110139","volume":"161","author":"S Auvin","year":"2024","unstructured":"Auvin S, Specchio N. Pharmacotherapeutic strategies for drug-resistant epilepsy in children. Epilepsy Behav. 2024;161: 110139. https:\/\/doi.org\/10.1016\/j.yebeh.2024.110139.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"710_CR3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069\u201377. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02397.x.","journal-title":"Epilepsia"},{"issue":"8","key":"710_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S1474-4422(23)00151-5","volume":"22","author":"E Perucca","year":"2023","unstructured":"Perucca E, Perucca P, White HS, Wirrell EC. Drug resistance in epilepsy. Lancet Neurol. 2023;22(8):723\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(23)00151-5.","journal-title":"Lancet Neurol"},{"issue":"6","key":"710_CR5","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","volume":"19","author":"E Perucca","year":"2020","unstructured":"Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544\u201356. https:\/\/doi.org\/10.1016\/S1474-4422(20)30035-1.","journal-title":"Lancet Neurol"},{"issue":"S2","key":"710_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/epi4.12268","volume":"3","author":"JM Rho","year":"2018","unstructured":"Rho JM, White HS. Brief history of anti-seizure drug development. Epilepsia Open. 2018;3(S2):114\u20139. https:\/\/doi.org\/10.1002\/epi4.12268.","journal-title":"Epilepsia Open."},{"key":"710_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2019.11.008","volume":"107","author":"MS Perry","year":"2020","unstructured":"Perry MS. New and emerging medications for treatment of pediatric epilepsy. Pediatr Neurol. 2020;107:24\u20137. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.11.008.","journal-title":"Pediatr Neurol"},{"key":"710_CR8","unstructured":"National Institute of Health and Care Excellence (NICE). NICE guideline [NG217]: epilepsies in children, young people and adults. 2022. https:\/\/www.nice.org.uk\/guidance\/ng217\/chapter\/5-Treating-epileptic-seizures-in-children-young-people-and-adults. Accessed 30 Jan 2025."},{"key":"710_CR9","unstructured":"UK Medicines and Healthcare products Regulatory Agency (MHRA). New valproate safety measures apply from 31 January. 2024. https:\/\/www.gov.uk\/government\/news\/new-valproate-safety-measures-apply-from-31-january#:~:text=From%20January%202024%2C%20valproate%20must,reproductive%20risks%20do%20not%20apply. Accessed 24 Mar 2025."},{"issue":"8","key":"710_CR10","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1111\/epi.18024","volume":"65","author":"L Tait","year":"2024","unstructured":"Tait L, Staniaszek LE, Galizia E, Martin-Lopez D, Walker MC, Azeez AAA, et al. Estimating the likelihood of epilepsy from clinically noncontributory electroencephalograms using computational analysis: a retrospective, multisite case-control study. Epilepsia. 2024;65(8):2459\u201369. https:\/\/doi.org\/10.1111\/epi.18024.","journal-title":"Epilepsia"},{"issue":"11","key":"710_CR11","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.3390\/ijerph18115780","volume":"18","author":"A Shoeibi","year":"2021","unstructured":"Shoeibi A, Khodatars M, Ghassemi N, Jafari M, Moridian P, Alizadehsani R, et al. Epileptic seizures detection using deep learning techniques: a review. Int J Environ Res Public Health. 2021;18(11):5780.","journal-title":"Int J Environ Res Public Health"},{"key":"710_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.5406","author":"M Ripart","year":"2025","unstructured":"Ripart M, Spitzer H, Williams LZJ, Walger L, Chen A, Napolitano A, et al. Detection of epileptogenic focal cortical dysplasia using graph neural networks: a MELD study. JAMA Neurol. 2025. https:\/\/doi.org\/10.1001\/jamaneurol.2024.5406.","journal-title":"JAMA Neurol"},{"key":"710_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109990","volume":"159","author":"A Biondi","year":"2024","unstructured":"Biondi A, Dursun E, Viana PF, Laiou P, Richardson MP. New wearable and portable EEG modalities in epilepsy: the views of hospital-based healthcare professionals. Epilepsy Behav. 2024;159: 109990. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109990.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"710_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/epi.17141","volume":"63","author":"BR Sheidley","year":"2022","unstructured":"Sheidley BR, Malinowski J, Bergner AL, Bier L, Gloss DS, Mu W, et al. Genetic testing for the epilepsies: a systematic review. Epilepsia. 2022;63(2):375\u201387. https:\/\/doi.org\/10.1111\/epi.17141.","journal-title":"Epilepsia"},{"issue":"12","key":"710_CR15","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamaneurol.2022.3651","volume":"79","author":"D McKnight","year":"2022","unstructured":"McKnight D, Morales A, Hatchell KE, Bristow SL, Bonkowsky JL, Perry MS, et al. Genetic testing to inform epilepsy treatment management from an international study of clinical practice. JAMA Neurol. 2022;79(12):1267\u201376. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3651.","journal-title":"JAMA Neurol"},{"key":"710_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00530","author":"A Ko","year":"2018","unstructured":"Ko A, Jung DE, Kim SH, Kang H-C, Lee JS, Lee ST, et al. The efficacy of ketogenic diet for specific genetic mutation in developmental and epileptic encephalopathy. Front Neurol. 2018. https:\/\/doi.org\/10.3389\/fneur.2018.00530.","journal-title":"Front Neurol"},{"key":"710_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejpn.2019.12.009","volume":"24","author":"E Musto","year":"2020","unstructured":"Musto E, Gardella E, M\u00f8ller RS. Recent advances in treatment of epilepsy-related sodium channelopathies. Eur J Paediatr Neurol. 2020;24:123\u20138. https:\/\/doi.org\/10.1016\/j.ejpn.2019.12.009.","journal-title":"Eur J Paediatr Neurol"},{"key":"710_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18257","author":"CE Gjerulfsen","year":"2025","unstructured":"Gjerulfsen CE, Oudin MJ, Furia F, Gverdtsiteli S, Landmark CJ, Trivisano M, et al. Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy. Epilepsia. 2025. https:\/\/doi.org\/10.1111\/epi.18257.","journal-title":"Epilepsia"},{"issue":"1","key":"710_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s13311-015-0403-5","volume":"13","author":"RS M\u00f8ller","year":"2016","unstructured":"M\u00f8ller RS, Johannesen KM. Precision medicine: SCN8A encephalopathy treated with sodium channel blockers. Neurotherapeutics. 2016;13(1):190\u20131. https:\/\/doi.org\/10.1007\/s13311-015-0403-5.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"710_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s13311-015-0372-8","volume":"13","author":"RS Boerma","year":"2016","unstructured":"Boerma RS, Braun KP, van de Broek MPH, van Berkestijn FMC, Swinkels ME, Hagebeuk EO, et al. Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics. 2016;13(1):192\u20137. https:\/\/doi.org\/10.1007\/s13311-015-0372-8.","journal-title":"Neurotherapeutics"},{"issue":"10","key":"710_CR21","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/epi.17332","volume":"63","author":"JK Knowles","year":"2022","unstructured":"Knowles JK, Helbig I, Metcalf CS, Lubbers Laura S, Isom LL, Demarest S, et al. Precision medicine for genetic epilepsy on the horizon: recent advances, present challenges, and suggestions for continued progress. Epilepsia. 2022;63(10):2461\u201375. https:\/\/doi.org\/10.1111\/epi.17332.","journal-title":"Epilepsia"},{"issue":"12","key":"710_CR22","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1111\/bcp.15479","volume":"88","author":"D Xu","year":"2022","unstructured":"Xu D, Chen S, Yang J, Wang X, Fang Z, Li M. Precision therapy with quinidine of KCNT1-related epileptic disorders: a systematic review. Br J Clin Pharmacol. 2022;88(12):5096\u2013112. https:\/\/doi.org\/10.1111\/bcp.15479.","journal-title":"Br J Clin Pharmacol"},{"key":"710_CR23","doi-asserted-by":"publisher","unstructured":"Bruno E, Simblett S, Lang A, Biondi A, Odoi C, Schulze-Bonhage A et al. Wearable technology in epilepsy: the views of patients, caregivers, and healthcare professionals. Epilepsy Behav. 2018;85:141\u20139. https:\/\/doi.org\/10.1016\/j.yebeh.2018.05.044.","DOI":"10.1016\/j.yebeh.2018.05.044"},{"issue":"13","key":"710_CR24","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s40265-019-01171-4","volume":"79","author":"V Franco","year":"2019","unstructured":"Franco V, Perucca E. Pharmacological and therapeutic properties of cannabidiol for epilepsy. Drugs. 2019;79(13):1435\u201354. https:\/\/doi.org\/10.1007\/s40265-019-01171-4.","journal-title":"Drugs"},{"key":"710_CR25","unstructured":"US Food and Drug Administration (FDA). Epidiolex (cannabidiol) prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/210365s021lbl.pdf. Accessed 25 Mar 2025."},{"key":"710_CR26","unstructured":"Electronic medicines compendium (emc). Epidyolex (cannabidiol) summary of product characteristics (SmPC). 2021. https:\/\/www.medicines.org.uk\/emc\/product\/10781\/smpc. Accessed 25 Mar 2025."},{"issue":"21","key":"710_CR27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611618.","journal-title":"N Engl J Med"},{"issue":"20","key":"710_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome. N Engl J Med. 2018;378(20):1888\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1714631.","journal-title":"N Engl J Med"},{"issue":"10125","key":"710_CR29","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox\u2013Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(18)30136-3.","journal-title":"Lancet"},{"issue":"3","key":"710_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","volume":"78","author":"EA Thiele","year":"2021","unstructured":"Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol. 2021;78(3):285\u201392. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4607.","journal-title":"JAMA Neurol"},{"issue":"6","key":"710_CR31","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/epi.16542","volume":"61","author":"M Bialer","year":"2020","unstructured":"Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia. 2020;61(6):1082\u20139. https:\/\/doi.org\/10.1111\/epi.16542.","journal-title":"Epilepsia"},{"issue":"6","key":"710_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/ane.13305","volume":"142","author":"O Devinsky","year":"2020","unstructured":"Devinsky O, Thiele EA, Wright S, Checketts D, Morrison G, Dunayevich E, et al. Cannabidiol efficacy independent of clobazam: meta-analysis of four randomized controlled trials. Acta Neurol Scand. 2020;142(6):531\u201340. https:\/\/doi.org\/10.1111\/ane.13305.","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"710_CR33","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/epi.16546","volume":"61","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Striano P, Zaccara G, Del Giovane C, Nardone R, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61(6):1090\u20138. https:\/\/doi.org\/10.1111\/epi.16546.","journal-title":"Epilepsia"},{"key":"710_CR34","unstructured":"European Medicines Agency (EMA). Epidyolex (cannabidiol). 2019. https:\/\/ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex. Accessed 25 Mar 2025."},{"issue":"1","key":"710_CR35","doi-asserted-by":"publisher","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske EP, J\u00f3\u017awiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2(1):16035. https:\/\/doi.org\/10.1038\/nrdp.2016.35.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"710_CR36","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","volume":"14","author":"P Curatolo","year":"2015","unstructured":"Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(15)00069-1.","journal-title":"Lancet Neurol"},{"issue":"13","key":"710_CR37","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345\u201356. https:\/\/doi.org\/10.1056\/NEJMra055323.","journal-title":"N Engl J Med"},{"issue":"1","key":"710_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","volume":"12","author":"JC Kingswood","year":"2017","unstructured":"Kingswood JC, d\u2019Aug\u00e8res GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA)\u2014baseline data on 2093 patients. Orphanet J Rare Dis. 2017;12(1):2. https:\/\/doi.org\/10.1186\/s13023-016-0553-5.","journal-title":"Orphanet J Rare Dis"},{"key":"710_CR39","unstructured":"US Food and Drug Administration (FDA). Affinator (everolimus) prescribing information. 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/203985s023,022334s051lbl.pdf. Accessed 25 Mar 2025."},{"key":"710_CR40","unstructured":"Electronic medicines compendium (emc). Votubia (everolimus) summary of product characteristics (SmPC). 2018. https:\/\/www.medicines.org.uk\/emc\/product\/7865\/smpc. Accessed 25 Mar 2025."},{"key":"710_CR41","unstructured":"European Medicines Agency (EMA). Votubia (everolimus). 2011. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/votubia. Accessed 25 Mar 2025."},{"issue":"10056","key":"710_CR42","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(16)31419-2.","journal-title":"Lancet"},{"key":"710_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1192022","author":"J Sourbron","year":"2023","unstructured":"Sourbron J, Lagae L. Fenfluramine: a plethora of mechanisms? Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1192022.","journal-title":"Front Pharmacol"},{"key":"710_CR44","unstructured":"US Food and Drug Administration (FDA). Fintepla (fenfluramine) prescribing information. 1973. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/212102s013lbl.pdf. Accessed 25 Mar 2025."},{"key":"710_CR45","unstructured":"Electronic medicines compendium (emc). Fintepla (fenfluramine) summary of product characteristics. 2020. https:\/\/www.medicines.org.uk\/emc\/product\/11998\/smpc. Accessed 25 Mar 2025."},{"key":"710_CR46","unstructured":"European Medicines Agency (EMA). Fintepla (fenfluramine). 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fintepla. Accessed 25 Mar 2025."},{"issue":"10216","key":"710_CR47","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/s0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243\u201354. https:\/\/doi.org\/10.1016\/s0140-6736(19)32500-0.","journal-title":"Lancet"},{"issue":"6","key":"710_CR48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","volume":"79","author":"KG Knupp","year":"2022","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox\u2013Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554\u201364. https:\/\/doi.org\/10.1001\/jamaneurol.2022.0829.","journal-title":"JAMA Neurol"},{"issue":"8","key":"710_CR49","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s40265-022-01724-0","volume":"82","author":"YN Lamb","year":"2022","unstructured":"Lamb YN. Ganaxolone: first approval. Drugs. 2022;82(8):933\u201340. https:\/\/doi.org\/10.1007\/s40265-022-01724-0.","journal-title":"Drugs"},{"issue":"11","key":"710_CR50","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/14737175.2021.1904895","volume":"21","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Riva A, Striano P. Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy. Expert Rev Neurother. 2021;21(11):1317\u201332. https:\/\/doi.org\/10.1080\/14737175.2021.1904895.","journal-title":"Expert Rev Neurother"},{"key":"710_CR51","unstructured":"US Food and Drug Administration (FDA). Ztalmy (ganaxolone) prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215904s003s004lbl.pdf. Accessed 25 Mar 2025."},{"key":"710_CR52","unstructured":"European Medicines Agency (EMA). Ztalmy (ganaxolone). 2023. https:\/\/www.ema.europa.eu\/en\/search?search_api_fulltext=ganaxolone&f%5B0%5D=ema_search_entity_is_document%3ADocument. Accessed 25 Mar 2025."},{"issue":"5","key":"710_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/s1474-4422(22)00077-1","volume":"21","author":"EMP Knight","year":"2022","unstructured":"Knight EMP, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, et al. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022;21(5):417\u201327. https:\/\/doi.org\/10.1016\/s1474-4422(22)00077-1.","journal-title":"Lancet Neurol"},{"key":"710_CR54","unstructured":"Marinus Pharmaceuticals Inc. Marinus pharmaceuticals announces topline results from phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex and commences process to explore strategic alternatives. 2024. https:\/\/ir.marinuspharma.com\/news\/news-details\/2024\/Marinus-Pharmaceuticals-Announces-Topline-Results-From-Phase-3-TrustTSC-Trial-of-Oral-Ganaxolone-in-Tuberous-Sclerosis-Complex-and-Commences-Process-to-Explore-Strategic-Alternatives\/default.aspx. Accessed 30 Jan 2025."},{"issue":"1","key":"710_CR55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14728214.2022.2059464","volume":"27","author":"AW Pong","year":"2022","unstructured":"Pong AW, Ross J, Tyrlikova I, Giermek AJ, Kohli MP, Khan YA, et al. Epilepsy: expert opinion on emerging drugs in phase 2\/3 clinical trials. Expert Opin Emerg Drugs. 2022;27(1):75\u201390. https:\/\/doi.org\/10.1080\/14728214.2022.2059464.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"710_CR56","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.nurt.2006.11.016","volume":"4","author":"GP Novak","year":"2007","unstructured":"Novak GP, Kelley M, Zannikos P, Klein B. Carisbamate (RWJ-333369). Neurotherapeutics. 2007;4(1):106\u20139. https:\/\/doi.org\/10.1016\/j.nurt.2006.11.016.","journal-title":"Neurotherapeutics"},{"key":"710_CR57","unstructured":"US Food and Drug Administration (FDA). Carisbamate\u2014treatment of Lennox\u2013Gastaut syndrome. 2017. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=594117. Accessed 25 Mar 2025."},{"key":"710_CR58","unstructured":"US Food and Drug Administration (FDA). Carisbamate\u2014management of patients with infantile spasms. 2012. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=362511. Accessed 25 Mar 2025."},{"issue":"3","key":"710_CR59","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2174\/1871527321666220113110044","volume":"22","author":"MA Barbieri","year":"2023","unstructured":"Barbieri MA, Perucca E, Spina E, Rota P, Franco V. Cenobamate: a review of its pharmacological properties, clinical efficacy and tolerability profile in the treatment of epilepsy. CNS Neurol Disord Drug Targets. 2023;22(3):394\u2013403. https:\/\/doi.org\/10.2174\/1871527321666220113110044.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"710_CR60","unstructured":"US Food and Drug Administration (FDA). Xcopri (cenobamate) prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212839s009s010lbl.pdf. Accessed 25 Mar 2025."},{"key":"710_CR61","unstructured":"Electronic medicines compendium (emc). Ontozry (cenobamate) summary of product characteristics (SmPC). 2021. https:\/\/www.medicines.org.uk\/emc\/product\/13010\/smpc. Accessed 25 Mar 2025."},{"key":"710_CR62","unstructured":"European Medicines Agency (EMA). Ontozry (cenobamate). 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ontozry. Accessed 25 Mar 2025."},{"issue":"22","key":"710_CR63","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/wnl.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322. https:\/\/doi.org\/10.1212\/wnl.0000000000009530.","journal-title":"Neurology"},{"issue":"1","key":"710_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348. https:\/\/doi.org\/10.1016\/S1474-4422(19)30399-0.","journal-title":"Lancet Neurol"},{"key":"710_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108679","volume":"130","author":"RT Varughese","year":"2022","unstructured":"Varughese RT, Shah YD, Karkare S, Kothare SV. Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study. Epilepsy Behav. 2022;130: 108679. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108679.","journal-title":"Epilepsy Behav"},{"key":"710_CR66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2022.01.001","volume":"129","author":"T Elliott","year":"2022","unstructured":"Elliott T, Ridley-Pryor T, Gienapp AJ, Wheless JW. Initial real-world experience with cenobamate in adolescents and adults: a single center experience. Pediatr Neurol. 2022;129:19\u201323. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2022.01.001.","journal-title":"Pediatr Neurol"},{"key":"710_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.950171","author":"KL Makridis","year":"2022","unstructured":"Makridis KL, Bast T, Prager C, Kovacevic-Preradovic T, Bittigau P, Mayer T, et al. Real-world experience treating pediatric epilepsy patients with cenobamate. Front Neurol. 2022. https:\/\/doi.org\/10.3389\/fneur.2022.950171.","journal-title":"Front Neurol"},{"key":"710_CR68","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pediatrneurol.2024.09.023","volume":"161","author":"G Aungaroon","year":"2024","unstructured":"Aungaroon G, Cooke A, Ritter D, Krueger D, Horn P, Franz DN. Cenobamate\u2019s efficacy for seizure treatment in tuberous sclerosis complex. Pediatr Neurol. 2024;161:201\u20137. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.09.023.","journal-title":"Pediatr Neurol"},{"issue":"7","key":"710_CR69","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s11064-017-2305-x","volume":"42","author":"G Dezsi","year":"2017","unstructured":"Dezsi G, Sieg F, Thomas M, O\u2019Brien TJ, van der Hart M, Jones NC. Disease-modifying effects of neural regeneration peptide 2945 in the GAERS model of absence epilepsy. Neurochem Res. 2017;42(7):2055\u201364. https:\/\/doi.org\/10.1007\/s11064-017-2305-x.","journal-title":"Neurochem Res"},{"key":"710_CR70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.npep.2014.11.002","volume":"49","author":"A Sajadian","year":"2015","unstructured":"Sajadian A, Esteghamat S, Karimzadeh F, Eshaghabadi A, Sieg F, Speckmann E-J, et al. Anticonvulsant effect of neural regeneration peptide 2945 on pentylenetetrazol-induced seizures in rats. Neuropeptides. 2015;49:15\u201323. https:\/\/doi.org\/10.1016\/j.npep.2014.11.002.","journal-title":"Neuropeptides"},{"key":"710_CR71","unstructured":"Curonz. Clinical studies by Curonz. 2021. https:\/\/www.curonz.com\/clinical.html. Accessed 03 Feb 2025."},{"key":"710_CR72","unstructured":"Curonz. Discovery. 2021. https:\/\/www.curonz.com\/discovery.html. Accessed 03 Feb 2025."},{"key":"710_CR73","unstructured":"Curonz. Clinical studies pipeline. 2021. https:\/\/www.curonz.com\/pipeline.html. Accessed 03 Feb 2025."},{"issue":"6","key":"710_CR74","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/epi.17232","volume":"63","author":"T Nishi","year":"2022","unstructured":"Nishi T, Metcalf CS, Fujimoto S, Hasegawa S, Miyamoto M, Sunahara E, et al. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor. Epilepsia. 2022;63(6):1580\u201390. https:\/\/doi.org\/10.1111\/epi.17232.","journal-title":"Epilepsia"},{"key":"710_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106646","volume":"174","author":"JJ Halford","year":"2021","unstructured":"Halford JJ, Sperling MR, Arkilo D, Asgharnejad M, Zinger C, Xu R, et al. A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies. Epilepsy Res. 2021;174: 106646. https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106646.","journal-title":"Epilepsy Res"},{"key":"710_CR76","doi-asserted-by":"publisher","unstructured":"Murthy NV, Asgharnejad M, Benitez A, Nakashima K, Kondo S. Proposed mechanism of action of soticlestat as an antiseizure medication (P9-1.013). Neurology. 2024;102(17_supplement_1):3060. https:\/\/doi.org\/10.1212\/WNL.0000000000204896.","DOI":"10.1212\/WNL.0000000000204896"},{"key":"710_CR77","unstructured":"Dravet Syndrome News. Soticlestat can reduce seizure frequency in adults with Dravet and other rare epilepsies initial data shows. 2019. https:\/\/dravetsyndromenews.com\/news\/soticlestat-can-reduce-seizure-frequency-dravet-syndrome-other-rare-epilepsies\/. Accessed 25 Mar 2025."},{"key":"710_CR78","unstructured":"European Medicines Agency (EMA). EU\/3\/21\/2529\u2014Orphan designation for treatment of Lennox\u2013Gastaut syndrome\u2014Soticlestat. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-21-2529. Accessed 25 Mar 2025."},{"issue":"10","key":"710_CR79","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/epi.17367","volume":"63","author":"CD Hahn","year":"2022","unstructured":"Hahn CD, Jiang Y, Villanueva V, Zolnowska M, Arkilo D, Hsiao S, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). Epilepsia. 2022;63(10):2671\u201383. https:\/\/doi.org\/10.1111\/epi.17367.","journal-title":"Epilepsia"},{"key":"710_CR80","unstructured":"Takeda Pharmaceutical Company Ltd. Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox\u2013Gastaut Syndrome. 2024. https:\/\/www.takeda.com\/newsroom\/newsreleases\/2024\/soticlestat-drevat-syndrom-phase3-results\/. Accessed 30 Jan 2025."},{"key":"710_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109173","volume":"142","author":"S Demarest","year":"2023","unstructured":"Demarest S, Jeste S, Agarwal N, Arkilo D, Asgharnejad M, Hsiao S, et al. Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE). Epilepsy Behav. 2023;142: 109173. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109173.","journal-title":"Epilepsy Behav"},{"key":"710_CR82","unstructured":"Takeda Pharmaceutical Company Ltd. Takeda provides update on soticlestat (TAK-935). 2025. https:\/\/www.takeda.com\/newsroom\/statements\/2025\/takeda-provides-update-on-soticlestat\/. Accessed 24 Mar 2025."},{"key":"710_CR83","unstructured":"Stoke Therapeutics. Stoke Therapeutics announces landmark new data that support the potential for STK-001 to be the first disease modifying medicine for the treatment of patients with Dravet syndrome. 2024. https:\/\/investor.stoketherapeutics.com\/news-releases\/news-release-details\/stoke-therapeutics-announces-landmark-new-data-support-potential. Accessed 24 Mar 2025."},{"key":"710_CR84","unstructured":"US Food and Drug Administration (FDA). Briviact (brivaracetam) prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/205836s014,205837s011,205838s011lbl.pdf. Accessed 18 Mar 2025."},{"issue":"7","key":"710_CR85","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1007\/s12325-024-02876-z","volume":"41","author":"P Klein","year":"2024","unstructured":"Klein P, Bourikas D. Narrative review of brivaracetam: preclinical profile and clinical benefits in the treatment of patients with epilepsy. Adv Ther. 2024;41(7):2682\u201399. https:\/\/doi.org\/10.1007\/s12325-024-02876-z.","journal-title":"Adv Ther"},{"key":"710_CR86","unstructured":"Electronic medicines compendium (emc). Briviact (brivaracetam) summary of product characteristics (SmPC). 2021. https:\/\/medicines.org.uk\/emc\/product\/10540\/smpc. Accessed 19 Mar 2025."},{"key":"710_CR87","unstructured":"European Medicines Agency. Briviact (brivaracetam). 2016. https:\/\/ema.europa.eu\/en\/medicines\/human\/EPAR\/briviact-italy-nubriveo#authorisation-details. Accessed 19 Mar 2025."},{"issue":"1","key":"710_CR88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/epi.12432","volume":"55","author":"P Ryvlin","year":"2014","unstructured":"Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47\u201356. https:\/\/doi.org\/10.1111\/epi.12432.","journal-title":"Epilepsia"},{"issue":"1","key":"710_CR89","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/epi.12433","volume":"55","author":"V Biton","year":"2014","unstructured":"Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57\u201366. https:\/\/doi.org\/10.1111\/epi.12433.","journal-title":"Epilepsia"},{"issue":"12","key":"710_CR90","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/epi.13212","volume":"56","author":"P Klein","year":"2015","unstructured":"Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890\u20138. https:\/\/doi.org\/10.1111\/epi.13212.","journal-title":"Epilepsia"},{"issue":"4","key":"710_CR91","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40272-019-00332-y","volume":"21","author":"E Liu","year":"2019","unstructured":"Liu E, Dilley D, McDonough B, Stockis A, Daniels T. Safety and tolerability of adjunctive brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial. Pediatr Drugs. 2019;21(4):291\u2013301. https:\/\/doi.org\/10.1007\/s40272-019-00332-y.","journal-title":"Pediatr Drugs"},{"issue":"11","key":"710_CR92","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1111\/epi.17754","volume":"64","author":"L Lagae","year":"2023","unstructured":"Lagae L, Klotz KA, Fogarasi A, Floricel F, Reichel C, Elshoff JP, et al. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: an open-label, follow-up trial. Epilepsia. 2023;64(11):2934\u201346. https:\/\/doi.org\/10.1111\/epi.17754.","journal-title":"Epilepsia"},{"key":"710_CR93","unstructured":"US Food and Drug Administration (FDA). Fycompa (perampanel) prescribing information. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202834s016,208277s004lbl.pdf. Accessed 19 Mar 2025."},{"key":"710_CR94","unstructured":"Electronic medicines compendium (emc). Fycompa (perampanel) summary of product characteristics (SmPC). 2012. https:\/\/medicines.org.uk\/emc\/product\/4276\/smpc. Accessed 19 Mar 2025."},{"key":"710_CR95","unstructured":"European Medicines Agency. Fycompa (perampanel). 2012. https:\/\/ema.europa.eu\/en\/medicines\/human\/EPAR\/fycompa#authorisation-details. Accessed 19 Mar 2025."},{"issue":"6","key":"710_CR96","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","volume":"79","author":"JA French","year":"2012","unstructured":"French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, et al. Adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;79(6):589\u201396. https:\/\/doi.org\/10.1212\/WNL.0b013e3182635735.","journal-title":"Neurology"},{"issue":"1","key":"710_CR97","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","volume":"54","author":"JA French","year":"2013","unstructured":"French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia. 2013;54(1):117\u201325. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03638.x.","journal-title":"Epilepsia"},{"issue":"18","key":"710_CR98","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","volume":"78","author":"GL Krauss","year":"2012","unstructured":"Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306. Neurology. 2012;78(18):1408\u201315. https:\/\/doi.org\/10.1212\/WNL.0b013e318254473a.","journal-title":"Neurology"},{"issue":"s1","key":"710_CR99","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/epi.12493","volume":"55","author":"BJ Steinhoff","year":"2014","unstructured":"Steinhoff BJ. Efficacy of perampanel: a review of pooled data. Epilepsia. 2014;55(s1):9\u201312. https:\/\/doi.org\/10.1111\/epi.12493.","journal-title":"Epilepsia"},{"issue":"11","key":"710_CR100","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","volume":"85","author":"JA French","year":"2015","unstructured":"French JA, Krauss GL, Wechsler RT, Wang X-F, DiVentura B, Brandt C, et al. Perampanel for tonic\u2013clonic seizures in idiopathic generalized epilepsy. Neurology. 2015;85(11):950\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000001930.","journal-title":"Neurology"},{"key":"710_CR101","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejpn.2024.02.008","volume":"50","author":"K Moretz","year":"2024","unstructured":"Moretz K, Wheless J, Santos C, Segal E, Lancman M, Patten A, et al. Phase IV PROVE study: perampanel in real-world clinical care of pediatric patients with epilepsy. Eur J Paediatr Neurol. 2024;50:23\u201330. https:\/\/doi.org\/10.1016\/j.ejpn.2024.02.008.","journal-title":"Eur J Paediatr Neurol"},{"key":"710_CR102","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.seizure.2022.02.011","volume":"98","author":"E Segal","year":"2022","unstructured":"Segal E, Wheless J, Moretz K, Penovich P, Patten A, Malhotra M. Perampanel in real-world clinical care of adolescent and adult patients with epilepsy: results from the retrospective phase IV PROVE study. Seizure. 2022;98:87\u201394. https:\/\/doi.org\/10.1016\/j.seizure.2022.02.011.","journal-title":"Seizure."},{"key":"710_CR103","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pediatrneurol.2024.10.015","volume":"162","author":"J Wheless","year":"2025","unstructured":"Wheless J, Weatherspoon S. Use of stiripentol in Dravet syndrome: a guide for clinicians. Pediatr Neurol. 2025;162:76\u201386. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.10.015.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"710_CR104","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s12325-024-02813-0","volume":"41","author":"A Bacq","year":"2024","unstructured":"Bacq A, Depaulis A, Castagn\u00e9 V, Le Guern M-E, Wirrell EC, Verleye M. An update on stiripentol mechanisms of action: a narrative review. Adv Ther. 2024;41(4):1351\u201371. https:\/\/doi.org\/10.1007\/s12325-024-02813-0.","journal-title":"Adv Ther"},{"key":"710_CR105","unstructured":"European Medicines Agency (EMA). Diacomit (stiripentol). 2007. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/diacomit#authorisation-details. Accessed 19 Mar 2025."},{"key":"710_CR106","unstructured":"US Food and Drug Administration (FDA). Diacomit (stiripentol) prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206709s000,207223s000lbl.pdf. Accessed 18 Mar 2025."},{"issue":"9242","key":"710_CR107","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, Rey E, d\u2019Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000;356(9242):1638\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(00)03157-3.","journal-title":"Lancet"},{"issue":"Suppl 8","key":"710_CR108","first-page":"155","volume":"43","author":"R Guerrini","year":"2002","unstructured":"Guerrini R, Tonnelier S, d\u2019Athis P, Rey E, Vincent J, Pons G. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial. Epilepsia. 2002;43(Suppl 8):155.","journal-title":"Epilepsia"},{"key":"710_CR109","unstructured":"US Food and Drug Administration (FDA). Sabril (vigabatrin) prescribing information. 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020427s025,022006s026lbl.pdf. Accessed 25 Mar 2025."},{"key":"710_CR110","unstructured":"Electronic medicines compendium (emc). Sabril (vigabatrin) summary of product characteristics (SmPC). 1989. https:\/\/www.medicines.org.uk\/emc\/product\/4279\/smpc. Accessed 25 Mar 2025."},{"key":"710_CR111","unstructured":"European Medicines Agency (EMA). Kigabeq (vigabatrin). 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kigabeq. Accessed 25 Mar 2025."},{"issue":"2","key":"710_CR112","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.25956","volume":"89","author":"K Kotulska","year":"2021","unstructured":"Kotulska K, Kwiatkowski DJ, Curatolo P, Weschke B, Riney K, Jansen F, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol. 2021;89(2):304\u201314. https:\/\/doi.org\/10.1002\/ana.25956.","journal-title":"Ann Neurol"},{"issue":"1","key":"710_CR113","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ana.26778","volume":"95","author":"EM Bebin","year":"2024","unstructured":"Bebin EM, Peters JM, Porter BE, McPherson TO, O\u2019Kelley S, Sahin M, et al. Early Treatment with vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial. Ann Neurol. 2024;95(1):15\u201326. https:\/\/doi.org\/10.1002\/ana.26778.","journal-title":"Ann Neurol"},{"key":"710_CR114","unstructured":"US Food and Drug Administration (FDA). Nayzilam (midazolam nasal spray) prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211321s000lbl.pdf. Accessed 25 Mar 2025."},{"key":"710_CR115","unstructured":"US Food and Drug Administration (FDA). Valtoco (diazepam nasal spray) prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/211635s008lbl.pdf. Accessed 25 Mar 2025."},{"issue":"9","key":"710_CR116","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/epi.15159","volume":"60","author":"K Detyniecki","year":"2019","unstructured":"Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng T-C, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters\u2014a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797\u2013808. https:\/\/doi.org\/10.1111\/epi.15159.","journal-title":"Epilepsia"},{"issue":"9","key":"710_CR117","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/epi.16300","volume":"60","author":"JW Wheless","year":"2019","unstructured":"Wheless JW, Meng T-C, Van Ess PJ, Detyniecki K, Sequeira DJ, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: an open-label extension trial. Epilepsia. 2019;60(9):1809\u201319. https:\/\/doi.org\/10.1111\/epi.16300.","journal-title":"Epilepsia"},{"key":"710_CR118","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2022.04.011","volume":"132","author":"D Tarquinio","year":"2022","unstructured":"Tarquinio D, Dlugos D, Wheless JW, Desai J, Carrazana E, Rabinowicz AL. Safety of diazepam nasal spray in children and adolescents with epilepsy: results from a long-term phase 3 safety study. Pediatr Neurol. 2022;132:50\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2022.04.011.","journal-title":"Pediatr Neurol"},{"issue":"9153","key":"710_CR119","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(98)06425-3","volume":"353","author":"RC Scott","year":"1999","unstructured":"Scott RC, Besag FMC, Neville BGR. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353(9153):623\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(98)06425-3.","journal-title":"Lancet"},{"issue":"9481","key":"710_CR120","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(05)66909-7","volume":"366","author":"J McIntyre","year":"2005","unstructured":"McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366(9481):205\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(05)66909-7.","journal-title":"Lancet"},{"key":"710_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108646","volume":"129","author":"P Kerezoudis","year":"2022","unstructured":"Kerezoudis P, Gyftopoulos A, Alexander AY, Keith Starnes D, Nickels KC, Worrell GA, et al. Safety and efficacy of responsive neurostimulation in the pediatric population: evidence from institutional review and patient-level meta-analysis. Epilepsy Behav. 2022;129: 108646. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108646.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"710_CR122","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3171\/2021.8.PEDS21201","volume":"29","author":"M Khan","year":"2022","unstructured":"Khan M, Paktiawal J, Piper RJ, Chari A, Tisdall MM. Intracranial neuromodulation with deep brain stimulation and responsive neurostimulation in children with drug-resistant epilepsy: a systematic review. J Neurosurg Pediatr. 2022;29(2):208\u201317. https:\/\/doi.org\/10.3171\/2021.8.PEDS21201.","journal-title":"J Neurosurg Pediatr"},{"key":"710_CR123","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.pediatrneurol.2023.03.001","volume":"143","author":"RK Singh","year":"2023","unstructured":"Singh RK, Eschbach K, Samanta D, Perry MS, Liu G, Alexander AL, et al. Responsive neurostimulation in drug-resistant pediatric epilepsy: findings from the Epilepsy Surgery Subgroup of the Pediatric Epilepsy Research Consortium. Pediatr Neurol. 2023;143:106\u201312. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.03.001.","journal-title":"Pediatr Neurol"},{"key":"710_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.108012","volume":"234","author":"AS Levy","year":"2023","unstructured":"Levy AS, Bystrom LL, Brown EC, Fajardo M, Wang S. Responsive neurostimulation for treatment of pediatric refractory epilepsy: a pooled analysis of the literature. Clin Neurol Neurosurg. 2023;234: 108012. https:\/\/doi.org\/10.1016\/j.clineuro.2023.108012.","journal-title":"Clin Neurol Neurosurg"},{"issue":"11","key":"710_CR125","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1007\/s00381-024-06546-x","volume":"40","author":"A Rosenberg","year":"2024","unstructured":"Rosenberg A, Wang R, Petchpradub M, Beaudreault C, Sacknovitz A, Cozzi FM, et al. Responsive neurostimulation in pediatric epilepsy: a systematic review and individual patient meta-analysis supplemented by a single institution case series in 105 aggregated patients. Child\u2019s Nerv Syst. 2024;40(11):3709\u201320. https:\/\/doi.org\/10.1007\/s00381-024-06546-x.","journal-title":"Child\u2019s Nerv Syst."},{"issue":"10","key":"710_CR126","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/acn3.51173","volume":"7","author":"C-S Kwon","year":"2020","unstructured":"Kwon C-S, Schupper AJ, Fields MC, Marcuse LV, La Vega-Talbott M, Panov F, et al. Centromedian thalamic responsive neurostimulation for Lennox\u2013Gastaut epilepsy and autism. Ann Clin Transl Neurol. 2020;7(10):2035\u201340. https:\/\/doi.org\/10.1002\/acn3.51173.","journal-title":"Ann Clin Transl Neurol"},{"key":"710_CR127","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pediatrneurol.2023.05.008","volume":"145","author":"C Karakas","year":"2023","unstructured":"Karakas C, Houck K, Handoko M, Trandafir C, Coorg R, Haneef Z, et al. Responsive neurostimulation for the treatment of children with drug-resistant epilepsy in tuberous sclerosis complex. Pediatr Neurol. 2023;145:97\u2013101. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.05.008.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"710_CR128","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/2022.7.Focus22331","volume":"53","author":"K Curtis","year":"2022","unstructured":"Curtis K, Hect JL, Harford E, Welch WP, Abel TJ. Responsive neurostimulation for pediatric patients with drug-resistant epilepsy: a case series and review of the literature. Neurosurg Focus. 2022;53(4):E10. https:\/\/doi.org\/10.3171\/2022.7.Focus22331.","journal-title":"Neurosurg Focus"},{"issue":"12","key":"710_CR129","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S1474-4422(21)00300-8","volume":"20","author":"P Ryvlin","year":"2021","unstructured":"Ryvlin P, Rheims S, Hirsch LJ, Sokolov A, Jehi L. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol. 2021;20(12):1038\u201347. https:\/\/doi.org\/10.1016\/S1474-4422(21)00300-8.","journal-title":"Lancet Neurol"},{"key":"710_CR130","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.seizure.2021.11.016","volume":"94","author":"N Muthiah","year":"2022","unstructured":"Muthiah N, Akwayena E, Vodovotz L, Sharma N, Jeong J-H, White GE, et al. Comparison of traditional and closed loop vagus nerve stimulation for treatment of pediatric drug-resistant epilepsy: a propensity-matched retrospective cohort study. Seizure. 2022;94:74\u201381. https:\/\/doi.org\/10.1016\/j.seizure.2021.11.016.","journal-title":"Seizure."},{"issue":"3","key":"710_CR131","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00381-021-05416-0","volume":"38","author":"B Santhumayor","year":"2022","unstructured":"Santhumayor B, Karkare S, Kothare S, Rodgers S. Evaluating vagus nerve stimulation treatment with heart rate monitoring in pediatric patients with intractable epilepsy. Child\u2019s Nerv Syst. 2022;38(3):547\u201356. https:\/\/doi.org\/10.1007\/s00381-021-05416-0.","journal-title":"Child\u2019s Nerv Syst."},{"key":"710_CR132","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.seizure.2021.02.015","volume":"86","author":"SA Abdelmoity","year":"2021","unstructured":"Abdelmoity SA, Abdelmoity AA, Riordan SM, Kaufman C, Le Pichon J-B, Abdelmoity A. The efficacy and tolerability of auto-stimulation-VNS in children with Lennox\u2013Gastaut syndrome. Seizure. 2021;86:168\u201374. https:\/\/doi.org\/10.1016\/j.seizure.2021.02.015.","journal-title":"Seizure."},{"key":"710_CR133","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.yebeh.2014.08.005","volume":"39","author":"L Aihua","year":"2014","unstructured":"Aihua L, Lu S, Liping L, Xiuru W, Hua L, Yuping W. A controlled trial of transcutaneous vagus nerve stimulation for the treatment of pharmacoresistant epilepsy. Epilepsy Behav. 2014;39:105\u201310. https:\/\/doi.org\/10.1016\/j.yebeh.2014.08.005.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"710_CR134","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3760\/cma.j.issn.0366-6999.20131511","volume":"127","author":"P Rong","year":"2014","unstructured":"Rong P, Liu A, Zhang J, Wang Y, Yang A, Li L, et al. An alternative therapy for drug-resistant epilepsy: transcutaneous auricular vagus nerve stimulation. Chin Med J. 2014;127(2):300\u20133.","journal-title":"Chin Med J"},{"key":"710_CR135","doi-asserted-by":"publisher","DOI":"10.1042\/cs20130518","author":"P Rong","year":"2014","unstructured":"Rong P, Liu A, Zhang J, Wang Y, He W, Yang A, et al. Transcutaneous vagus nerve stimulation for refractory epilepsy: a randomized controlled trial. Clin Sci. 2014. https:\/\/doi.org\/10.1042\/cs20130518.","journal-title":"Clin Sci"},{"issue":"3","key":"710_CR136","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.yebeh.2013.02.001","volume":"28","author":"W He","year":"2013","unstructured":"He W, Jing X, Wang X, Rong P, Li L, Shi H, et al. Transcutaneous auricular vagus nerve stimulation as a complementary therapy for pediatric epilepsy: a pilot trial. Epilepsy Behav. 2013;28(3):343\u20136. https:\/\/doi.org\/10.1016\/j.yebeh.2013.02.001.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"710_CR137","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.neurom.2022.07.007","volume":"26","author":"C Sigrist","year":"2023","unstructured":"Sigrist C, Torki B, Bolz L-O, Jeglorz T, Bolz A, Koenig J. Transcutaneous auricular vagus nerve stimulation in pediatric patients: a systematic review of clinical treatment protocols and stimulation parameters. Neuromodulation. 2023;26(3):507\u201317. https:\/\/doi.org\/10.1016\/j.neurom.2022.07.007.","journal-title":"Neuromodulation"},{"key":"710_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.107074","volume":"190","author":"F Ashrafzadeh","year":"2023","unstructured":"Ashrafzadeh F, Akhondian J, Hashemi N, Esmaeilzadeh M, Ghanaee A, Yavarzadeh H, et al. Therapeutical impacts of transcranial direct current stimulation on drug-resistant epilepsy in pediatric patients: a double-blind parallel-group randomized clinical trial. Epilepsy Res. 2023;190: 107074. https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107074.","journal-title":"Epilepsy Res"},{"issue":"4","key":"710_CR139","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.brs.2013.01.009","volume":"6","author":"N Auvichayapat","year":"2013","unstructured":"Auvichayapat N, Rotenberg A, Gersner R, Ngodklang S, Tiamkao S, Tassaneeyakul W, et al. Transcranial direct current stimulation for treatment of refractory childhood focal epilepsy. Brain Stimul. 2013;6(4):696\u2013700. https:\/\/doi.org\/10.1016\/j.brs.2013.01.009.","journal-title":"Brain Stimul"},{"key":"710_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2016.00066","author":"N Auvichayapat","year":"2016","unstructured":"Auvichayapat N, Sinsupan K, Tunkamnerdthai O, Auvichayapat P. Transcranial direct current stimulation for treatment of childhood pharmacoresistant Lennox\u2013Gastaut syndrome: a pilot study. Front Neurol. 2016. https:\/\/doi.org\/10.3389\/fneur.2016.00066.","journal-title":"Front Neurol"},{"key":"710_CR141","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.seizure.2022.06.009","volume":"100","author":"D San-Juan","year":"2022","unstructured":"San-Juan D, Ruiz AG, Arriola AB, Pesqueira GQ, Ruffini G, Trenado C. Safety and efficacy of cathodal transcranial direct current stimulation in patients with Lennox\u2013Gastaut Syndrome: an open-label, prospective, single-center, single-blinded, pilot study. Seizure. 2022;100:44\u201350. https:\/\/doi.org\/10.1016\/j.seizure.2022.06.009.","journal-title":"Seizure."},{"issue":"2","key":"710_CR142","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/02656736.2020.1769868","volume":"37","author":"M Remick","year":"2020","unstructured":"Remick M, McDowell MM, Gupta K, Felker J, Abel TJ. Emerging indications for stereotactic laser interstitial thermal therapy in pediatric neurosurgery. Int J Hyperth. 2020;37(2):84\u201393. https:\/\/doi.org\/10.1080\/02656736.2020.1769868.","journal-title":"Int J Hyperth"},{"key":"710_CR143","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.seizure.2018.12.010","volume":"77","author":"C Hoppe","year":"2020","unstructured":"Hoppe C, Helmstaedter C. Laser interstitial thermotherapy (LiTT) in pediatric epilepsy surgery. Seizure. 2020;77:69\u201375. https:\/\/doi.org\/10.1016\/j.seizure.2018.12.010.","journal-title":"Seizure."},{"issue":"5","key":"710_CR144","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000491823","volume":"53","author":"I Fayed","year":"2018","unstructured":"Fayed I, Sacino Matthew F, Gaillard Willilam D, Keating Robert F, Oluigbo CO. MR-guided laser interstitial thermal therapy for medically refractory lesional epilepsy in pediatric patients: experience and outcomes. Pediatr Neurosurg. 2018;53(5):322\u20139. https:\/\/doi.org\/10.1159\/000491823.","journal-title":"Pediatr Neurosurg"},{"issue":"10","key":"710_CR145","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/epi.13106","volume":"56","author":"EC Lewis","year":"2015","unstructured":"Lewis EC, Weil AG, Duchowny M, Bhatia S, Ragheb J, Miller I. MR-guided laser interstitial thermal therapy for pediatric drug-resistant lesional epilepsy. Epilepsia. 2015;56(10):1590\u20138. https:\/\/doi.org\/10.1111\/epi.13106.","journal-title":"Epilepsia"},{"issue":"1","key":"710_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2023.8.PEDS23158","volume":"33","author":"MI Barros Guinle","year":"2024","unstructured":"Barros Guinle MI, Johnstone T, Li D, Kaur H, Porter BE, Grant GA. Approach, complications, and outcomes for 37 consecutive pediatric patients undergoing laser ablation for medically refractory epilepsy at Stanford Children\u2019s Health. J Neurosurg Pediatr. 2024;33(1):1\u201311. https:\/\/doi.org\/10.3171\/2023.8.PEDS23158.","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"710_CR147","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.3171\/2018.6.FOCUS18228","volume":"45","author":"Z Tovar-Spinoza","year":"2018","unstructured":"Tovar-Spinoza Z, Ziechmann R, Zyck S. Single and staged laser interstitial thermal therapy ablation for cortical tubers causing refractory epilepsy in pediatric patients. Neurosurg Focus. 2018;45(3):E9. https:\/\/doi.org\/10.3171\/2018.6.FOCUS18228.","journal-title":"Neurosurg Focus"},{"key":"710_CR148","doi-asserted-by":"publisher","DOI":"10.1177\/08830738241312262","author":"AM Trivedi","year":"2025","unstructured":"Trivedi AM, Montenegro MA, Gonda D, Kim-McManus O, Rismanchi N, Frederick A, et al. Laser interstitial thermal therapy for the treatment of mesial temporal lobe epilepsy in children. J Child Neurol. 2025. https:\/\/doi.org\/10.1177\/08830738241312262.","journal-title":"J Child Neurol"},{"issue":"5","key":"710_CR149","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00381-022-05491-x","volume":"38","author":"JL Hect","year":"2022","unstructured":"Hect JL, Alattar AA, Harford EE, Reecher H, Fernandes DT, Esplin N, et al. Stereotactic laser interstitial thermal therapy for the treatment of pediatric drug-resistant epilepsy: indications, techniques, and safety. Childs Nerv Syst. 2022;38(5):961\u201370. https:\/\/doi.org\/10.1007\/s00381-022-05491-x.","journal-title":"Childs Nerv Syst"},{"issue":"6","key":"710_CR150","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3171\/2017.6.PEDS17158","volume":"20","author":"MS Perry","year":"2017","unstructured":"Perry MS, Donahue DJ, Malik SI, Keator CG, Hernandez A, Reddy RK, et al. Magnetic resonance imaging\u2013guided laser interstitial thermal therapy as treatment for intractable insular epilepsy in children. J Neurosurg Pediatr. 2017;20(6):575\u201382. https:\/\/doi.org\/10.3171\/2017.6.PEDS17158.","journal-title":"J Neurosurg Pediatr"},{"issue":"6","key":"710_CR151","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3171\/2022.12.PEDS22282","volume":"31","author":"EV Arocho-Quinones","year":"2023","unstructured":"Arocho-Quinones EV, Lew SM, Handler MH, Tovar-Spinoza Z, Smyth MD, Bollo RJ, et al. Magnetic resonance imaging\u2013guided stereotactic laser ablation therapy for the treatment of pediatric epilepsy: a retrospective multiinstitutional study. J Neurosurg Pediatr. 2023;31(6):551\u201364. https:\/\/doi.org\/10.3171\/2022.12.PEDS22282.","journal-title":"J Neurosurg Pediatr"},{"key":"710_CR152","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.seizure.2024.07.017","volume":"122","author":"ALL Larcipretti","year":"2024","unstructured":"Larcipretti ALL, Gomes FC, Udoma-Udofa OC, Dagostin CS, de Oliveira JS, Nager GB, et al. Magnetic resonance-guided laser interstitial thermal therapy versus open surgical corpus callosotomy for pediatric refractory epilepsy: a systematic review and meta-analysis. Seizure. 2024;122:45\u201351. https:\/\/doi.org\/10.1016\/j.seizure.2024.07.017.","journal-title":"Seizure."},{"issue":"9","key":"710_CR153","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1111\/epi.17679","volume":"64","author":"DJ Aum","year":"2023","unstructured":"Aum DJ, Reynolds RA, McEvoy S, Tomko S, Zempel J, Roland JL, et al. Surgical outcomes of open and laser interstitial thermal therapy approaches for corpus callosotomy in pediatric epilepsy. Epilepsia. 2023;64(9):2274\u201385. https:\/\/doi.org\/10.1111\/epi.17679.","journal-title":"Epilepsia"},{"issue":"1","key":"710_CR154","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/epi.17451","volume":"64","author":"O Yossofzai","year":"2023","unstructured":"Yossofzai O, Stone S, Madsen J, Moineddin R, Wang S, Ragheb J, et al. Seizure outcome of pediatric magnetic resonance-guided laser interstitial thermal therapy versus open surgery: a matched noninferiority cohort study. Epilepsia. 2023;64(1):114\u201326. https:\/\/doi.org\/10.1111\/epi.17451.","journal-title":"Epilepsia"},{"issue":"4","key":"710_CR155","doi-asserted-by":"publisher","first-page":"E730","DOI":"10.1093\/neuros\/nyz094","volume":"85","author":"AT Hale","year":"2019","unstructured":"Hale AT, Sen S, Haider AS, Perkins FFJ, Clarke DF, Lee MR, et al. Open resection versus laser interstitial thermal therapy for the treatment of pediatric insular epilepsy. Neurosurgery. 2019;85(4):E730\u20136. https:\/\/doi.org\/10.1093\/neuros\/nyz094.","journal-title":"Neurosurgery"},{"key":"710_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106644","volume":"205","author":"AG Brotis","year":"2021","unstructured":"Brotis AG, Giannis T, Paschalis T, Kapsalaki E, Dardiotis E, Fountas KN. A meta-analysis on potential modifiers of LITT efficacy for mesial temporal lobe epilepsy: seizure-freedom seems to fade with time. Clin Neurol Neurosurg. 2021;205: 106644. https:\/\/doi.org\/10.1016\/j.clineuro.2021.106644.","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"710_CR157","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3171\/2020.7.PEDS20167","volume":"27","author":"JP Caruso","year":"2021","unstructured":"Caruso JP, Janjua MB, Dolce A, Price AV. Retrospective analysis of open surgical versus laser interstitial thermal therapy callosotomy in pediatric patients with refractory epilepsy. J Neurosurg Pediatr. 2021;27(4):420\u20138. https:\/\/doi.org\/10.3171\/2020.7.PEDS20167.","journal-title":"J Neurosurg Pediatr"},{"key":"710_CR158","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/j.wneu.2018.09.074","volume":"121","author":"C-H Kuo","year":"2019","unstructured":"Kuo C-H, Feroze AH, Poliachik SL, Hauptman JS, Novotny EJ, Ojemann JG. Laser ablation therapy for pediatric patients with intracranial lesions in eloquent areas. World Neurosurg. 2019;121:e191\u20139. https:\/\/doi.org\/10.1016\/j.wneu.2018.09.074.","journal-title":"World Neurosurg."},{"issue":"8","key":"710_CR159","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.neurom.2022.08.449","volume":"26","author":"A Cukiert","year":"2023","unstructured":"Cukiert A, Cukiert CM, Burattini JA, Guimaraes RB. Combined neuromodulation (vagus nerve stimulation and deep brain stimulation) in patients with refractory generalized epilepsy: an observational study. Neuromodulation. 2023;26(8):1742\u20136. https:\/\/doi.org\/10.1016\/j.neurom.2022.08.449.","journal-title":"Neuromodulation"},{"issue":"6","key":"710_CR160","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3171\/2023.1.PEDS22486","volume":"31","author":"CP Beaudreault","year":"2023","unstructured":"Beaudreault CP, Spirollari E, Naftchi AF, Sukul V, Das A, Vazquez S, et al. Safety of vagus nerve stimulation and responsive neurostimulation used in combination for multifocal and generalized onset epilepsy in pediatric patients. J Neurosurg Pediatr. 2023;31(6):565\u201373. https:\/\/doi.org\/10.3171\/2023.1.PEDS22486.","journal-title":"J Neurosurg Pediatr"},{"issue":"5","key":"710_CR161","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00701-016-2765-9","volume":"158","author":"M Katagiri","year":"2016","unstructured":"Katagiri M, Iida K, Kagawa K, Hashizume A, Ishikawa N, Hanaya R, et al. Combined surgical intervention with vagus nerve stimulation following corpus callosotomy in patients with Lennox\u2013Gastaut syndrome. Acta Neurochir. 2016;158(5):1005\u201312. https:\/\/doi.org\/10.1007\/s00701-016-2765-9.","journal-title":"Acta Neurochir"},{"key":"710_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11111395","author":"K Hatano","year":"2021","unstructured":"Hatano K, Fujimoto A, Yamamoto T, Enoki H, Okanishi T. Effects of vagus nerve stimulation following corpus callosotomy for patients with drug-resistant epilepsy. Brain Sci. 2021. https:\/\/doi.org\/10.3390\/brainsci11111395.","journal-title":"Brain Sci"},{"issue":"1","key":"710_CR163","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10143-024-03078-5","volume":"47","author":"A Soltani Khaboushan","year":"2024","unstructured":"Soltani Khaboushan A, Zafari R, Sabahi M, Khorasanizadeh M, Dabbagh Ohadi MA, Flouty O, et al. Focused ultrasound for treatment of epilepsy: a systematic review and meta-analysis of preclinical and clinical studies. Neurosurg Rev. 2024;47(1):839. https:\/\/doi.org\/10.1007\/s10143-024-03078-5.","journal-title":"Neurosurg Rev"},{"key":"710_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e43001","author":"L Hogeveen","year":"2025","unstructured":"Hogeveen L, Boon P, Mertens A, Verhagen L, Vonck K. Therapeutic use of transcranial ultrasound for epilepsy: a review. Heliyon. 2025. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e43001.","journal-title":"Heliyon."},{"key":"710_CR165","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev-genom-120219-074937","volume":"21","author":"P Perucca","year":"2020","unstructured":"Perucca P, Bahlo M, Berkovic SF. The genetics of epilepsy. Annu Rev Genom Hum Genet. 2020;21:205\u201330. https:\/\/doi.org\/10.1146\/annurev-genom-120219-074937.","journal-title":"Annu Rev Genom Hum Genet."},{"issue":"2","key":"710_CR166","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/wco.0000000000001349","volume":"38","author":"MC Walker","year":"2025","unstructured":"Walker MC. State-of-the-art gene therapy in epilepsy. Curr Opin Neurol. 2025;38(2):128\u201334. https:\/\/doi.org\/10.1097\/wco.0000000000001349.","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"710_CR167","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s12519-024-00843-w","volume":"20","author":"A-J Cai","year":"2024","unstructured":"Cai A-J, Gao K, Zhang F, Jiang Y-W. Recent advances and current status of gene therapy for epilepsy. World J Pediatr. 2024;20(11):1115\u201337. https:\/\/doi.org\/10.1007\/s12519-024-00843-w.","journal-title":"World J Pediatr."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00710-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:40:38Z","timestamp":1770043238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00710-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":167,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["710"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00710-9","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"29 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received in relation to the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"R.F.M.C. was a principal investigator in a GW Pharma sponsored trial of cannabidiol for the treatment of Lennox\u2013Gastaut syndrome. He has received honoraria from, has provided paid consultation for, and has awarded educational grants from Jazz Pharmaceuticals and UCB. F.M.C.B. is an Editorial Board member of\n                      Pediatric Drugs\n                      . F.M.C.B. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. F.M.C.B. and M.J.V. have no competing interests to declare that are relevant to the topics covered in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the drafting of the manuscript and approved the final version for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}